Supernus Pharmaceuticals (NASDAQ:SUPN) Stock Rating Lowered by Wall Street Zen

Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Several other analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Zacks Research raised Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Cantor Fitzgerald increased their price target on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, July 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $62.83.

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $47.64 on Friday. Supernus Pharmaceuticals has a 12-month low of $40.26 and a 12-month high of $59.68. The firm has a 50-day moving average price of $46.17 and a 200-day moving average price of $48.92. The firm has a market capitalization of $2.77 billion, a PE ratio of -24.81, a price-to-earnings-growth ratio of 0.78 and a beta of 0.56.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of SUPN. Royal Bank of Canada grew its position in shares of Supernus Pharmaceuticals by 68.1% during the 1st quarter. Royal Bank of Canada now owns 11,669 shares of the specialty pharmaceutical company’s stock worth $382,000 after buying an additional 4,729 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 35.2% in the first quarter. AQR Capital Management LLC now owns 85,224 shares of the specialty pharmaceutical company’s stock valued at $2,791,000 after acquiring an additional 22,182 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Supernus Pharmaceuticals by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,860 shares of the specialty pharmaceutical company’s stock worth $978,000 after acquiring an additional 1,297 shares during the period. Millennium Management LLC lifted its stake in Supernus Pharmaceuticals by 370.5% in the first quarter. Millennium Management LLC now owns 143,356 shares of the specialty pharmaceutical company’s stock worth $4,695,000 after acquiring an additional 112,886 shares during the period. Finally, Empowered Funds LLC grew its holdings in Supernus Pharmaceuticals by 16.0% during the 1st quarter. Empowered Funds LLC now owns 48,045 shares of the specialty pharmaceutical company’s stock worth $1,573,000 after acquiring an additional 6,619 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.